Navigation Links
Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
Date:9/1/2009

CAMBRIDGE, Massachusetts, September 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today reported that it has completed its submission of a New Drug Application (NDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, with the U.S. Food and Drug Administration (FDA). The Company also announced positive results from the final two Phase III studies of velaglucerase alfa, with both studies reaching all of their primary and secondary endpoints.

"The submission of the NDA for velaglucerase alfa, earlier than previously announced, is an important milestone for Shire, bringing us another step closer to providing a new treatment option for patients with Type 1 Gaucher disease," said Sylvie Gregoire, President of Shire Human Genetic Therapies. "We are also pleased to report that the data from our final two Phase III trials met our expectations by reaching all of their primary and secondary endpoints, demonstrating consistency with the results recently reported from the first Phase III trial. In addition, we are on-track to submit our European filing for velaglucerase alfa by the end of 2009."

Shire's velaglucerase alfa program included the largest and most comprehensive set of Phase III clinical trials conducted to date for Gaucher disease. Over 100 patients at 24 sites in 10 countries around the world have participated in the clinical studies.

"I am impressed by the series of clinical trials that were designed to evaluate velaglucerase alfa at multiple doses and in different patient groups," said Dr. Christine Eng, Professor of Molecular and Human Genetics, Baylor College of Medicine. "The inclusion of children, who are often the sickest
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
2. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
3. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
4. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
5. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
6. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
7. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
8. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
9. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
10. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
11. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FLINT, Mich. , Dec. 24, 2014  Diplomat ... largest independent specialty pharmacy, is proud to announce ... and quality at Diplomat, will take office as the ... 2015. The formal induction ceremony will take place Feb. ... which will be held at the Renaissance Center in ...
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, ... of over-the-counter (OTC) medicinal and healthcare products, announced it ... MigraPure® H, a hemp-based, advanced headache relief product, for ... in Colorado , Washington ... With the MigraPure H Advanced headache relief ...
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
Breaking Medicine Technology:Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... Risk Based on Clinical Data, ... WALTHAM, Mass., July 22 Interleukin Genetics,Inc. (Amex: ... an enhanced test report,format and information package for ... currently marketed under the brand name Gensona(R) Heart ...
... The SEAS (Simvastatin and Ezetimibe in,Aortic Stenosis) ... with the combination of simvastatin (40 mg daily) ... stenosis., Aortic stenosis (which involves partial blockage ... relatively common disease among older people in Western,populations. ...
Cached Medicine Technology:Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4
(Date:12/25/2014)... Product liability lawsuits filed in the ... http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal court, ... in the U.S. District Court, Northern District of Ohio ... conference on January 7, 2015, at the Paul G. ... Palm Beach, Florida. The Conference is scheduled to begin ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... common during the holidays, but there are strategies that can ... arrive at a party hungry. It may seem logical to ... party, but deprivation leads to hunger, and hunger leads to ... Mount Kisco, N.Y., said in a hospital news release. ... to have a snack before attending a party when you ...
(Date:12/25/2014)... 25, 2014 Thousands of transvaginal mesh ... in a number of multidistrict litigations currently underway in ... Liebhard LLP reports. According to an Order issued on ... a Joint Status Conference in all of the proceedings ... been directed to submit a proposed agenda to the ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... lumpectomy linked to depression, fear, study finds , , WEDNESDAY, ... who opt for breast-conserving cancer surgery say they now ... their quality of life, a new study says. , ... were twice as likely to fear their cancer returning ...
... jump in number of those over 70 who are ,doing ... comes to sex, grandma and grandpa are having more of ... the study, the last quarter century has seen a dramatic ... whether married or unmarried. And as an added bonus, seniors ...
... MLAB ) announced today that it has been ... of the 100 fastest-growing,publicly held small companies in the ... with annual revenues of less than $200 million and,rank ... and stock,performance over the past three years. This was ...
... -- China Medicine,Corporation (OTC Bulletin Board: CHME; ... leading distributor and developer of ethical and,over-the-counter ... supplements, medical devices, and medical formulations in ... that it released a white,paper on Recombinant ...
... 9 Nyer Medical Group,Inc. (Nasdaq: NYER ... Medical Supplies,Inc., ("ADCO South") its Florida Medical-Surgical division. ... was awarded a two-year,contract with Sunrise Senior Living, ... 16 of the company,s Assisted Living Facilities in,Massachusetts. ...
... Texas, July 9 SKINTASTIC(TM),Medical and Surgical Rejuvenation ... FDA-approved EVOLENCE(R) -- the latest injectable collagen filler,in ... EVOLENCE(R) boasts immediate, predictable visible results, with little,swelling. ... EVOLENCE(R) in a,comparison study against a popular dermal ...
Cached Medicine News:Health News:Breast-Conserving Surgery Leaves Many Cancer Patients Disappointed 2Health News:Seniors Having More Sex Than Ever 2Health News:Seniors Having More Sex Than Ever 3Health News:Mesa Laboratories, Inc. Named to Fortune Small Business Magazine's 2008 List 2Health News:China Medicine Releases White Paper on Developing Recombinant Aflatoxin-Detoxifizyme 2Health News:Nyer Medical Group, Inc. Announces Sale of Company's Florida Medical-Surgical Division; Pharmacy Division Awarded Two-Year Preferred Supplier Contract 2Health News:Nyer Medical Group, Inc. Announces Sale of Company's Florida Medical-Surgical Division; Pharmacy Division Awarded Two-Year Preferred Supplier Contract 3Health News:New Injectable Collagen Filler Offers Natural Results 2
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
... pH: pH(4.7%, H 2 O): 7.0 ... 47% Potassium Phosphate Dibasic: 25% Potassium Phosphate Monobasic: ... powder per liter of purified water. Autoclave. Application: ... proteins than LB media by allowing for greater ...
...
Medicine Products: